Cases & Deals

Apsara establishes global patent portfolio for aquaporin-4 antibodies

Clients Apsara Therapeutics, Inc.

Jones Day represents Apsara Therapeutics, Inc. in the establishment of a global patent portfolio relating to aquaporin-4 (AQP4) antibodies for the treatment of neuromyelitis optica.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.